Previous findings on the role of AR in advanced PCa stimulated the chemical search for novel AR signaling inhibitors such as enzalutamide, apalutamide, or darolutamide, which improved the survival of PCa patients.1 The gene discussed is AR; the disease is posterior cortical atrophy.